Eli Lilly names new head of cancer drug business

Print
Email
|

Associated Press

Posted on February 11, 2011 at 12:01 PM

Updated Friday, Feb 11 at 12:01 PM

INDIANAPOLIS (AP) — Eli Lilly and Co. on Friday named company insider Sue Mahony as president of its cancer drug business.

The change is effective immediately. Mahony has worked at Eli Lilly for about 10 years, the company said. Before her promotion she was in charge of human resources and diversity. The company said her earlier positions included general manager of its Canadian business. She worked for other drugmakers, including Amgen Inc., Bristol-Myers Squibb Co., and Schering-Plough Corp. for about 10 years before joining Eli Lilly.

Mahony is replacing John Johnson, who resigned Jan. 28 for family and personal reasons. Johnson is the former CEO of ImClone Systems, which Lilly acquired in 2008.

The company said Steve Fry will assume Mahony's previous human resources and diversity position. Fry was in charge of human resources for Lilly's bio-medicines and emerging markets units.

Eli Lilly shares fell 42 cents to $35.20 in pre-market trading.

Print
Email
|